Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172225 | 0.90 | HTR2A (0.46) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL8926 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29792655 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL3533385 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL17351757 | 0.80 | IDO1 (0.46) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL489675 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| Bromide SCHEMBL15741709 | 0.80 | TAAR1 (0.50) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL489913 | 0.80 | HTR2A (0.48) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29835952 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29783095 | 0.80 | HTR2A (0.48) | HTR2AHTR2CIDO1TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3456721-B1 | METHOD OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIVITORY ACTIVITY | SHIONOGI & CO (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3456721-A2 | METHOD OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIVITORY ACTIVITY | Shionogi & Co., Ltd (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-3127908-B1 | PROCESS FOR PREPARING COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10125146-B2 | Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate | SHIONOGI & CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-10125147-B2 | Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate | SHIONOGI & CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-10000508-B2 | Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate | SHIONOGI & CO., LTD (JP) | 2018-06-19 | — | — | US | disclosed |
| US-9969750-B2 | Method of producing (3S,11aR)-6,8-dihalo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-diones | SHIONOGI AND CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| US-20180044351-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180037593-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20180037591-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150038702-A1 | Method of producing compounds having HIV integrase inhivitory activity | SHINOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8865907-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | SHINOGI & CO., LTD (JP) | 2014-01-09 | — | — | US | disclosed |
| EP-2602260-A1 | PROCESS FOR PREPARING COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2412709-A1 | PROCESS FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | Shionogi & Co., Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10125146-B2 | Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate | H1-4, CYP4Z1, H1-2 | HTR2A 178/4885HTR2C 128/4885IDO1 1386/4885 |
| US-20150038702-A1 | Method of producing compounds having HIV integrase inhivitory activity | XDH, IMPDH1, IMPA1 | HTR2A 3205/4885HTR2C 2519/4885IDO1 42/4885 |
| US-10125147-B2 | Crystalline methyl (4R,12aS)-7-(benzyloxy)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylate | PYM1, DRD4, MBD2 | HTR2A 302/4885HTR2C 128/4885IDO1 730/4885 |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1536/4885HTR2C 1662/4885IDO1 33/4885 |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1427/4885HTR2C 1594/4885IDO1 25/4885 |
| US-20180044351-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | CYP3A4, DRD4, CCND2 | HTR2A 3022/4885HTR2C 1871/4885IDO1 230/4885 |
| US-10000508-B2 | Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarboxylate | DPYD, ODC1, PKD1 | HTR2A 1553/4885HTR2C 851/4885IDO1 1006/4885 |
| US-20140011995-A1 | Process for Preparing Compound Having HIV Integrase Inhibitory Activity | DRD4, XDH, CCND2 | HTR2A 3060/4885HTR2C 2007/4885IDO1 189/4885 |
| US-20180037593-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | HTR2A 2840/4885HTR2C 1791/4885IDO1 135/4885 |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1427/4885HTR2C 1594/4885IDO1 25/4885 |
| US-20180037591-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | HTR2A 2840/4885HTR2C 1791/4885IDO1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.